Therapy With Direct-Acting Antiviral Agents for Hepatitis
C in Liver Transplant Recipients.
Nogueras López F, López Garrido A, Ortega Suazo EJ,
Transplant Proc.
2018 Mar;50(2):631-633.
Abstract
FULL-TEXT ARTICLE
Use of direct-acting antiviral agents in
hepatitis C virus-infected liver transplant candidates.
Gadiparthi C, Cholankeril G, Perumpail BJ, et
al
World J Gastroenterol.
2018 Jan 21;24(3):315-322.
Paper
HCV Antiviral Therapy In Liver Transplant Candidates and Recipients with
Renal Insufficiency.
Verna EC, Brown RS Jr.
Transplantation. 2017
Feb 16.
Abstract
Developing therapies to treat hepatitis C infection in
post-liver transplant recipients.
McCarty TR, Lim JK.
Expert Opin Pharmacother.
2016 Dec 26
Abstract
Successful continuation of HCV treatment following liver
transplantation.
Carrillo CF, Crespo G, de la
Revilla J, et al
Tansplantation.
2016 Dec 1..
Abstract
Hepatitis C in Liver Allograft Recipients: Utility of
One-Year Post-Transplantation Biopsy as an Indicator of Antiviral Therapy.
Habib S, Malik S, Fu B,
et al
Gastroenterology Res. 2015
Dec;8(6):281-290.
Abstract
Management of post liver transplantation recurrent hepatitis
C infection with directly acting antiviral drugs: a review.
Jothimani D, Govil S, Rela M.
Hepatol Int. 2016 Jun
23.
Abstract
Liver Support With Albumin Dialysis Reduces Hepatitis C Virus Viremia and
Facilitates Antiviral Treatment of Severe Hepatitis C Virus Recurrence After
Liver Transplantation.
Ibáñez-Samaniego L, Catalina MV, Rincón D,
et al
Ther Apher Dial. 2016 Mar 1.
Abstract
FULL-TEXT ARTICLE
Impact of new
treatment options for hepatitis C virus infection in liver transplantation.
Righi E, Londero A, Carnelutti A, et al
World J Gastroenterol.
2015 Oct 14;21(38):10760-75
Paper
Strategies to manage hepatitis C virus (HCV) infection
disease burden - volume 2.
Gane E,
Kershenobich D, Seguin-Devaux C ,et
al
J
Viral Hepat. 2015 Jan;22 Suppl
1:46-73
Abstract
Optimal therapy in HCV liver transplant patients with direct
acting antivirals.
Coilly A, Roche B, Duclos-Vallée
JC, Samuel D.
Liver Int. 2014 Nov
6.
Abstract
Impact of Antiviral Treatment on Survival in HCV-Positive
Liver Recipients.
Wawrzynowicz-Syczewska M, Zeair S, et al
Ann Transplant.
2014 Jul 30;19:367-72.
Abstract
High Post-Transplant Virologic Response in Hepatitis C Virus Infected
Patients Treated with Pre-Transplant
Protease Inhibitor-Based Triple Therapy.
Verna EC, Shetty K, Lukose T, et al
Liver Int. 2014 Jun
6. .
Abstract
A US Multicenter Study of Hepatitis C Treatment
of Liver Transplant Recipients with Protease-Inhibitor Triple Therapy.
Burton JR Jr, O'Leary JG, Verna EC, et al
J Hepatol. 2014 May 3.
Abstract
Rescue therapy with intravenous silibinin in liver transplant recipients
with recurrent HCV hepatitis - two case reports.
Socha L, Karpińska E, Jurczyk K, Laurans L, et al
Ann Transplant. 2014 Apr 8;19:161-4.
Abstract
Antiviral prophylaxis for the prevention of
chronic hepatitis C virus in patients undergoing liver transplantation.
Gurusamy KS, Tsochatzis E, Toon CD, et
al
Cochrane Database Syst Rev.
2013 Dec 2;12:CD006573
Abstract
Drug-drug interactions with oral anti-HCV agents and
Idiosyncratic Hepatotoxicity in the Liver Transplant setting.
Tischer S, Fontana RJ.
J Hepatol. 2013 Nov 23.
.
Abstract
Safety and Efficacy of Protease Inhibitors to Treat Hepatitis C After Liver
Transplantation: a Multicenter Experience.
Audrey C, Bruno R, Jérôme D, Vincent
L, et al
J Hepatol.
2013 Aug 29 et al.
Abstract
Preemptive antiviral treatment for hepatitis C virus after living
donor liver transplantation.
Sugawara Y, Tamura S, Yamashiki N,
et al
Transplant Proc. 2012 Apr;44(3):791-3..
Abstract |
HCV
Liver
Transplants
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
